Boris Johnson Visits Fujifilm for Covid-19 Vaccine Update
FUJIFILM Diosynth Biotechnologies site in Billingham, Teesside, United Kingdom.

Boris Johnson Visits Fujifilm for Covid-19 Vaccine Update

UK Prime Minister Boris Johnson today visited Fujifilm Diosynth Biotechnologies, a world leading contract development and manufacturing organization. Fujifilm are based in Teesside at its Billingham site and Boris meet the team working to support the manufacture of a new Covid-19 vaccine candidate.

During the visit, Boris Johnson toured the Fujifilm Diosynth Biotechnologies facilities where the antigen component (active ingredient) of Novavax’ NVX-CoV2373 COVID-19 vaccine will be manufactured as well as other life-impacting therapies. Fujifilm’s leading technical expertise in baculovirus systems and biopharmaceutical manufacturing excellence is contracted by Novavax to produce antigen for up to 180 million vaccine doses.

coronavirus vaccine

Boris Johnson toured the laboratories and manufacturing facilities and was explained the science and technology behind Fujifilm’s work by a small number of the site’s 850-strong workforce who are playing a crucial role in vaccine production.

Prime Minister Boris Johnson later said, “I was delighted to visit Fujifilm today, and hear from Paul FoundSarah MaxfieldAbigail TyermanJonathan Haigh and others about the work being done to manufacture the Novavax vaccine, currently in Phase 3 clinical trials.”

banner

“If approved, Novavax will further strengthen our already record breaking vaccine rollout. The work of the team here to get this vaccine ready showcases some of the very best of British science and manufacturing.”

“I’m hugely proud of the efforts here at Fujifilm, as we all come together to beat this pandemic. I urge you all to keep up this vital work, helping to get those vaccines into arms and protecting our most vulnerable.”

Boris Johnson's visit to Fujifilm. Nurse about to give Covid-19 vaccine injection.

Paul Found, CEO of Fujifilm Diosynth Biotechnologies, UK, said, “As we prepare for production, we were extremely honoured to host the Prime Minister at our state-of-the-art development and manufacturing facilities on Teesside. During the tour, the Prime Minister had great interest in seeing our science and technology at work, and speaking with a small number of our talented team who are working on the Novavax COVID-19 vaccine programme. The entire Fujifilm team feels a strong sense of pride that we are contributing to help address the pandemic.”

Novavax initiated Phase 3 clinical trial in the UK in September 2020. In January 2021, the company announced that NVX-CoV2373 met the primary endpoint, with a vaccine efficacy in the UK Phase 3 trial as a result of the first interim analysis. The vaccine was shown to be 89.3% effective in preventing coronavirus in participants, as well as efficacy against new UK variant.

Fujifilm Diosynth Biotechnologies logo
Source: FUJIFILM Diosynth Biotechnologies. Logo. Feb. 13, 2021. https://fujifilmdiosynth.com/

 

About Fujifilm

Fujifilm Diosynth Biotechnologies is an industry-leading Biologics Contract  Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North CarolinaCollege Station, Texas and Hillerød, Denmark.  Fujifilm Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Fujifilm Diosynth Biotechnologies is a partnership between Fujifilm Corporation and Mitsubishi Corporation.

Fujifilm Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar.

rtSource: Fujifilm Diosynth Biotechnologies.

picturebox1

Ivan Golden | Owner/Founder of THX News, Goldiers, LoversBee & SublimeBTC. British/American entrepreneur since 1991. Former tennis player, bookseller & fine art dealer.